Cambridge Healthtech Institute’s 7th Annual

CAR Ts, TCRs and TILs

Engineering Clinically Relevant Adoptive T Cell Therapies

May 6-7, 2020

Cambridge Healthtech Institute’s 7th Annual CAR Ts, TCRs and TILs focuses on the latest tools, techniques, and engineering strategies driving the development of cellular immunotherapies for cancer and immune disorders. Focus will be given to clinical progress with Chimeric Antigen Receptors (CAR), T Cell Receptors (TCR), Tumor Infiltrating Lymphocytes (TIL) and Natural Killer (NK) cells, with dedicated sessions on off-the-shelf platforms, solid tumors and lessons learnt from the clinic.

Preliminary Agenda

TRANSLATIONAL SUCCESS IN CAR T

Development, Clinical Results and Translational Analysis of a T Cell Product for Mantle Cell Lymphoma

Adrian Bot, PhD, Vice President, Translational Sciences, Kite Pharma, a Gilead Company

Progress in Solid Tumors: CAR T Therapy in Mesothelioma – An Update

Prasad S. Adusumilli, MD, FACS FCCP, Deputy Chief and Associate Attending, Thoracic Surgery; Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center (CTC), Memorial Sloan-Kettering Cancer Center; Associate Professor, Cardiothoracic Surgery, Weill Cornell Medicine

ALLOGENIC, OFF-THE-SHELF THERAPIES

Latest Developments in Allogenic T Cell Therapy

Tom Van Blarcom, PhD, Head, Protein Engineering, Allogene Therapeutics

Gene Edited Off-the-Shelf Immunotherapies

Laurent Poirot, PhD, Vice President, Immunology, Cellectis

Non-Gene-Edited Allogeneic CAR T Cells: Maximizing Safety and Persistence

Peggy Sotiropoulou, PhD, Director, Research & Development, Celyad

Translation of Pluripotent Cell-Derived T and NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy

Bob Valamehr, PhD, Chief Development Officer, Fate Therapeutics

TCRs

New Broadly Expressed Cancer Targets from Successful TIL Therapy

Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Infection & Immunity, Cardiff University School of Medicine

A Novel TCR Engineering Approach to Eliminate Tumor Cells

Rajkumar Ganesan, PhD, Director, Antibody Engineering, Bispecifics and CAR T

Clinical Experience with T Cells Expressing NY-ESO-1 TCR and CRISPR Edited to Eliminate Endogenous TCR and PD-1

Simon F. Lacey, PhD, Director, Translational and Correlative Studies Laboratory, Center for Cellular Immunotherapies, University of Pennsylvania

TILs

Tumor-Infiltrating Lymphocytes Therapy for Solid Tumors

Chantale Bernatchez, PhD, Assistant Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Advancements in Tumor-Infiltrating Lymphocytes in Treatment of Solid Tumors

Corrine Epperly, Senior Vice President, Strategy and Operations, Iovance Biotherapeutics

* The program is subject to change without notice, due to unforeseen reason.